



Suggested Formula	Epinephrine 5 mcg/mL, Lidocaine Hydrochloride 10 mg/mL Intravenous Injection (Solution, 3 mL)	FIN	F 004 764v2
-------------------	---	-----	-------------

**SUGGESTED FORMULATION**

Ingredient Listing	Qty.	Unit	NDC #	Supplier	Lot Number	Expiry Date
Epinephrine 0.025 mg/mL Stock Solution	0.60	mL				
Lidocaine Hydrochloride 12.5 mg/mL Stock Solution	2.40	mL				
<b>† Epinephrine 1 mg/mL Stock Solution</b>						
Epinephrine, USP	0.100	g				
Sterile Water For Injection, USP	90.0	mL				
Sterile Water For Injection, USP	q.s. to 100.0	mL				
Hydrochloric Acid 10% Solution	As required					
<b>†† Epinephrine 0.025 mg/mL Stock Solution</b>						
Epinephrine 1 mg/mL Stock Solution	1.00	mL				
Sodium Chloride, USP	0.36	g				
Sterile Water For Injection, USP	30.0	mL				
Sterile Water For Injection, USP	q.s. to 40.0	mL				
<b>††† Lidocaine Hydrochloride 12.5 mg/mL Stock Solution</b>						
Lidocaine Hydrochloride, USP	0.125	g				
Citric Acid (Anhydrous), USP	0.09	g				
Sodium Citrate (Dihydrate), USP	0.20	g				
Benzyl Alcohol, NF	0.1	mL				
Sterile Water For Injection, USP	8.0	mL				
Sterile Water For Injection, USP	q.s. to 10.0	mL				



Suggested Formula	Epinephrine 5 mcg/mL, Lidocaine Hydrochloride 10 mg/mL Intravenous Injection (Solution, 3 mL)	FIN	F 004 764v2
-------------------	---	-----	-------------

## SPECIAL PREPARATORY CONSIDERATIONS

### Ingredient-Specific Information

**Light sensitive** (protect from light whenever possible): *Epinephrine, Benzyl Alcohol*

**Narrow Therapeutic Index** *Lidocaine Hydrochloride*

**Air sensitive** (protect from air whenever possible): *Epinephrine*

### Suggested Preparatory Guidelines

Non-Sterile Preparation     Sterile Preparation

#### Processing Error /

#### Testing Considerations:

#### Special Instruction:

To account for processing error considerations during preparation, it is suggested to measure an additional **30 to 40%** of the required quantities of ingredients.

This formula must be prepared within the appropriate facilities under adequate environmental conditions, following the necessary guidelines and procedures as stated within *USP 797*. Only trained and qualified personnel must prepare this formula.

All heat stable, reusable materials and equipment must be sterilized and depyrogenated by dry heat sterilization at 250°C for 2 hours prior to use.

Every batch of final product compounded using this procedure must be sterility and endotoxin tested before being dispensed.

#### **Lidocaine Hydrochloride has a narrow therapeutic index.**

Protective apparel, such as a sterile gown, sterile gloves, shoe covers, head cap, eyewear and face-masks should always be worn. In addition, proper personnel cleansing must be done before entering the buffer or clean area.

Filter integrity must be validated by performing a filter stress test. If the test demonstrates that the filter might be defective, the solution must be discarded and remade.

This procedure requires the use of very small quantities of ingredients. All calculations and preparation techniques must be verified before dispensing the final product.



Suggested Formula	Epinephrine 5 mcg/mL, Lidocaine Hydrochloride 10 mg/mL Intravenous Injection (Solution, 3 mL)	FIN	F 004 764v2
-------------------	---	-----	-------------

**SUGGESTED PREPARATION (for 3 mL)**

Weigh and / or measure the following ingredients when appropriate:

Ingredient Listing	Qty.	Unit	Multiplication factor (*): ____	Processing Error	Qty. to measure
Epinephrine 0.025 mg/mL Stock Solution §	0.60	mL			
Lidocaine Hydrochloride 12.5 mg/mL Stock Solution §	2.40	mL			
<b>† Epinephrine 1 mg/mL Stock Solution</b>					
Epinephrine, USP §	0.100	g	---	---	
Sterile Water For Injection, USP §	90.0	mL	---	---	
Sterile Water For Injection, USP §	q.s. to 100.0	mL	---	---	
Hydrochloric Acid 10% Solution §	As required				
<b>†† Epinephrine 0.025 mg/mL Stock Solution</b>					
Epinephrine 1 mg/mL Stock Solution §	1.00	mL	---	---	
Sodium Chloride, USP §	0.36	g	---	---	
Sterile Water For Injection, USP §	30.0	mL	---	---	
Sterile Water For Injection, USP §	q.s. to 40.0	mL	---	---	
<b>††† Lidocaine Hydrochloride 12.5 mg/mL Stock Solution</b>					
Lidocaine Hydrochloride, USP §	0.125	g	---	---	
Citric Acid (Anhydrous), USP §	0.09	g	---	---	
Sodium Citrate (Dihydrate), USP §	0.20	g	---	---	
Benzyl Alcohol, NF §	0.1	mL	---	---	
Sterile Water For Injection, USP §	8.0	mL	---	---	
Sterile Water For Injection, USP §	q.s. to 10.0	mL	---	---	

\* Takes into account increased batch size conversions and density conversions, if required.

§ Weigh / measure just prior to use.



Suggested Formula	Epinephrine 5 mcg/mL, Lidocaine Hydrochloride 10 mg/mL Intravenous Injection (Solution, 3 mL)	FIN	F 004 764v2
-------------------	---	-----	-------------

Preparatory Instruction

**IMPORTANT: All preparatory procedures must be performed using proper Aseptic Technique**

1.	<b><u>Equipment sterilization:</u></b> Following the manufacturer's specifications, sterilize and depyrogenate all heat stable, reusable materials and equipment, then return to ambient temperature.
2.	<b>† <u>Epinephrine 1 mg/mL Stock Solution preparation:</u></b>  A. Incrementally add the Epinephrine (0.100 g) to the Sterile Water for Injection (90.0 mL). Then, <b><u>VERY SLOWLY</u></b> add and mix the Hydrochloric Acid 10% Solution in a drop-wise manner into the mixture. Test the pH of the solution. It should lie between 4.8 and 5.2.  <u>Specifications:</u> Continuously mix until all solid particles have completely dissolved.  <u>End result:</u> Homogeneous liquid-like solution.  B. Add additional Sterile Water for Injection to the mixture (Step 2A) to fill to the required amount (100.0 mL).  <u>Specifications:</u> Continuously mix.  <u>End result:</u> Homogeneous liquid-like solution.
3.	<b>†† <u>Epinephrine 0.025 mg/mL Stock Solution preparation:</u></b>  A. Sequentially add the following ingredients into the Sterile Water for Injection (30.0 mL).  -Epinephrine 1 mg/mL Stock Solution (1.00 mL) -Sodium Chloride  <u>Specifications:</u> Continuously mix until all solid particles have completely dissolved.  <u>End result:</u> Homogeneous liquid-like solution.  B. Add additional Sterile Water for Injection to the mixture (Step 3A) to fill to the required amount (40.0 mL).  <u>Specifications:</u> Continuously mix.  <u>End result:</u> Homogeneous liquid-like solution.



Suggested Formula	Epinephrine 5 mcg/mL, Lidocaine Hydrochloride 10 mg/mL Intravenous Injection (Solution, 3 mL)	FIN	F 004 764v2
4.	<p>††† <b><u>Lidocaine Hydrochloride 12.5 mg/mL Stock Solution preparation:</u></b></p> <p>A. Sequentially add the following ingredients into the Sterile Water for Injection (8.0 mL).</p> <ul style="list-style-type: none"><li>-Lidocaine Hydrochloride</li><li>-Citric Acid (Anhydrous)</li><li>-Sodium Citrate (Dihydrate)</li><li>-Benzyl Alcohol</li></ul> <p><u>Specifications:</u> Continuously mix until all solid particles have completely dissolved.</p> <p><u>End result:</u> Homogeneous liquid-like solution.</p> <p>B. Add additional Sterile Water for Injection to the mixture (Step 4A) to fill to the required amount (10.0 mL).</p> <p><u>Specifications:</u> Continuously mix.</p> <p><u>End result:</u> Homogeneous liquid-like solution.</p>		
5.	<p><b><u>Medium integration:</u></b></p> <p>A. Incrementally add the Epinephrine 0.05 mg/mL Stock Solution (0.60 mL <i>plus</i> processing error adjustments) to the Lidocaine Hydrochloride 12.5 mg/mL Stock Solution (2.40 mL <i>plus</i> processing error adjustments).</p> <p><u>Specifications:</u> Continuously mix.</p> <p><u>End result:</u> Homogeneous liquid-like solution.</p>		
6.	<p><b><u>Filtering and transferring:</u></b></p> <p>Aseptically filter the solution through a 0.22-µm sterile filter into the recommended dispensing container (see Packaging requirements). Transfer the remainder into a separate dispensing container. This is to be used as the Test sample for sterility and endotoxin testing.</p>		
7.	<p><b><u>Filter integrity test:</u></b></p> <p>Validate filter integrity by performing a filter stress test. If the test demonstrates that the filter might be defective, the solution must be discarded and remade.</p>		
8.	<p><b><u>Sterility testing:</u></b></p> <p>Validate the Test sample for sterility and endotoxins, in accordance to current USP 797 regulatory guidelines.</p>		



Suggested Formula	Epinephrine 5 mcg/mL, Lidocaine Hydrochloride 10 mg/mL Intravenous Injection (Solution, 3 mL)	FIN	F 004 764v2
-------------------	---	-----	-------------

### SUGGESTED PRESENTATION

Estimated Beyond-Use Date	14 days, refrigerated, as per USP. BUD based on a successful sterility and endotoxin test result.	Packaging Requirements	Sterile, tightly closed, light-resistant unit-dose injection vials.	
Auxiliary Labels	1	Use as directed. Do not exceed prescribed dose.	6	Do not used if product changes color.
	2	Keep out of reach of children.	7	Protect from light.
	3	Keep refrigerated. Do not freeze.	8	Discard container after use.
	4	Do not take with alcohol, sleep aids, tranquilizers or other CNS depressants.	9	May impair mental and/or physical ability. Use care when operating a car or machinery.
	5	Consult your health care practitioner if any other prescription or over-the-counter medications are currently being used or are prescribed for future use.	10	Discard in the presence of particulate matter.
Pharmacist Instructions	Add any auxiliary labels specific to the active ingredients to the dispensing container as deemed necessary.			
Patient Instructions	Contact your pharmacist in the event of adverse reactions.			



Suggested Formula	Epinephrine 5 mcg/mL, Lidocaine Hydrochloride 10 mg/mL Intravenous Injection (Solution, 3 mL)	FIN	F 004 764v2
-------------------	---	-----	-------------

## REFERENCES

1.	Parenteral Preparations. In: Allen, LV, Jr. <i>The Art, Science and Technology of Pharmaceutical Compounding Third Edition</i> . American Pharmaceutical Association; 2008: 313.
2.	Benzyl Alcohol. In: Rowe RC. <i>Handbook of Pharmaceutical Excipients, 6<sup>th</sup> Edition</i> . American Pharmaceutical Association; 2009: 64.
3.	Epinephrine. In: Sweetman SC, ed. <i>Martindale: The Complete Drug Reference, 36<sup>th</sup> Edition</i> . London, England: The Pharmaceutical Press; 2009: 1203.
4.	Lidocaine Hydrochloride. In: Sweetman SC, ed. <i>Martindale: The Complete Drug Reference, 36<sup>th</sup> Edition</i> . London, England: The Pharmaceutical Press; 2009: 1862.
5.	Epinephrine (Monograph). In: O'Neil MJ. <i>The Merck Index 14<sup>th</sup> Edition</i> . Whitehouse Station, NJ: Merck & Co, Inc.; 2006: Monograph #3619.
6.	Lidocaine (Monograph). In: O'Neil MJ. <i>The Merck Index 14<sup>th</sup> Edition</i> . Whitehouse Station, NJ: Merck & Co, Inc.; 2006: Monograph #5482.
7.	Epinephrine. In: Trissel LA. <i>Trissel's Stability of Compounded Formulations, 3<sup>rd</sup> Edition</i> . American Pharmaceutical Association; 2005: 159.
8.	Lidocaine Hydrochloride. In: Trissel LA. <i>Trissel's Stability of Compounded Formulations, 3<sup>rd</sup> Edition</i> . American Pharmaceutical Association; 2005: 253.
9.	Epinephrine. <i>United States Pharmacopeia XXXII / National Formulary 27</i> . Rockville, MD. US Pharmacopeial Convention, Inc. 2009: 2260.
10.	Lidocaine Hydrochloride (Monograph). <i>United States Pharmacopeia XXXII / National Formulary 27</i> . Rockville, MD. US Pharmacopeial Convention, Inc. 2009: 2781.
11.	USP <797>. <i>United States Pharmacopeia XXXII / National Formulary 27</i> . Rockville, MD. US Pharmacopeial Convention, Inc. 2009: 318.

**DISCLAIMER: MEDISCA NETWORK INC. & RÉSEAU MEDISCA NETWORK INC., HEREBY REFERRED TO AS 'THE NETWORK', HAVE PROVIDED THE FORMULA AND INSTRUCTIONS ABOVE AS A MODEL FOR EDUCATIONAL PURPOSES ONLY ON THE BASIS OF THE RECOGNIZED COMPENDIA AND TEXTS REFERENCED AT THE END OF THIS DOCUMENT. THE NETWORK TAKES NO RESPONSIBILITY FOR THE VALIDITY OR ACCURACY OF THIS INFORMATION OR FOR ITS SAFETY OR EFFECTIVENESS, NOR FOR ANY USE THEREOF, WHICH IS AT THE SOLE RISK OF THE LICENSED PHARMACIST. ADJUSTMENTS MAY BE NEEDED TO MEET SPECIFIC PATIENT NEEDS AND IN ACCORDANCE WITH A LICENSED PRESCRIBER'S PRESCRIPTION. THE PHARMACIST MUST EMPLOY APPROPRIATE TESTS TO DETERMINE THE STABILITY OF THIS SUGGESTED FORMULA. THE NETWORK CANNOT BE HELD LIABLE TO ANY PERSON OR ENTITY CONCERNING CLAIMS, LOSS, OR DAMAGE CAUSED BY, OR ALLEGED TO BE CAUSED BY, DIRECTLY OR INDIRECTLY, THE USE OR MISUSE OF THE INFORMATION CONTAINED IN THIS SUGGESTED FORMULA. IN ALL CASES IT IS THE RESPONSIBILITY OF THE LICENSED PHARMACIST TO KNOW THE LAW, TO COMPOUND ANY FINISHED PRODUCT AND TO DISPENSE THESE PRODUCTS IN ACCORDANCE WITH FEDERAL AND STATE LAW.**